Cargando…

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults

BACKGROUND: This phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults. METHODS: We enrolled 42 healthy, BCG-vaccinated adults into 4 grou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilkie, Morven, Satti, Iman, Minhinnick, Alice, Harris, Stephanie, Riste, Michael, Ramon, Raquel Lopez, Sheehan, Sharon, Thomas, Zita-Rose Manjaly, Wright, Daniel, Stockdale, Lisa, Hamidi, Ali, O'Shea, Matthew K., Dwivedi, Kritica, Behrens, Hannah Michaela, Davenne, Tamara, Morton, Joshua, Vermaak, Samantha, Lawrie, Alison, Moss, Paul, McShane, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985898/ https://www.ncbi.nlm.nih.gov/pubmed/31735500 http://dx.doi.org/10.1016/j.vaccine.2019.10.102

Ejemplares similares

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2019)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015)

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
por: Minhinnick, Alice, et al.
Publicado: (2016)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
por: Riste, Michael, et al.
Publicado: (2021)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
por: Satti, Iman, et al.
Publicado: (2014)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
por: Tameris, Michele, et al.
Publicado: (2014)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: McShane, Helen, et al.
Publicado: (2016)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017)

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
por: Wajja, Anne, et al.
Publicado: (2018)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
por: Matsumiya, Magali, et al.
Publicado: (2014)

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2008)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

MVA85A vaccine to enhance BCG for preventing tuberculosis
por: Kashangura, Rufaro, et al.
Publicado: (2019)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2011)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, Angela M, et al.
Publicado: (2011)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination
por: Bunyasi, E. W., et al.
Publicado: (2017)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: Kashangura, Rufaro, et al.
Publicado: (2015)

Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
por: Dieye, Tandakha N., et al.
Publicado: (2013)

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A
por: Tanner, Rachel, et al.
Publicado: (2014)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
por: Dieye, Tandakha N., et al.
Publicado: (2013)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
por: Betts, Gareth, et al.
Publicado: (2012)

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
por: Ndiaye, Birahim Pierre, et al.
Publicado: (2015)

EXM 85-21: 31/10 - 85
por: Malandain, E.
Publicado: (1985)

Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A
por: Griffiths, Kristin L., et al.
Publicado: (2011)

Picasso 85 /
por: Rodríguez-Aguilera, Cesáreo
Publicado: (1968)

CCM 85-
Publicado: (1985)

Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines
por: Kandeel, Mahmoud, et al.
Publicado: (2023)

Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A
por: Matsumiya, Magali, et al.
Publicado: (2013)

On the decay of 90Nb, 89m,89 Nb 85m,85Y and 85mSr (Abstract)
por: Arlt, R, et al.
Publicado: (1970)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
por: Tameris, Michele D, et al.
Publicado: (2013)

MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques
por: Verreck, Frank A. W., et al.
Publicado: (2009)

EXM 85-2
por: Philippe, J
Publicado: (1985)

Cannot write session to /tmp/vufind_sessions/sess_n88e4bm2ih23a4qtq41rdhiu0h